Correction to: Leukemia ; https://doi.org/10.1038/leu.2017.276; published online: 30 August 2017
Following the publication of this article the authors noted that data describing precisely where phosphorylation sites in proteins modulated following JAK1 or JAK3 inhibition in mutant T-ALL samples was not clearly annotated. Therefore an additional sheet has been added to Supplementary Table 2.
The authors wish to apologize for any inconvenience caused.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Degryse, S., de Bock, C.E., Demeyer, S. et al. Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32, 2731 (2018). https://doi.org/10.1038/s41375-018-0241-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0241-7
